Click link below picture
.
Here’s how you know CRISPR, the revolutionary gene-editing technology getting all kinds of hype around the web, is poised to go mainstream: Big Pharma’s getting in the game.
It was recently announced that a $300 million joint venture between Bayer AG (best known for its aspirin) and bio startup CRISPR Therapeutics will aim to develop drugs for blindness, blood disorders and congenital heart disease. It’s a logical next step, especially since scientists at a Los Angeles-based medical institute recently proved they could use CRISPR/Cas9 to treat a type of inheritable blindness in mice.
For a little background, CRISPR/Cas9 gives scientists the ability to directly modify or correct changes in our genome, especially ones that come from disease, by “cutting” the genes with a protein called Cas9, which you might call the scissors. When CRISPR is successful, it means that we can change a busted protein — like one from cancer or HIV — and fully correct the problem.
.
Image Credit: Getty Images
.
.
Click link below for article:
.
__________________________________________
James' World 2 